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Introduction
Obstructive sleep apnea (OSA) is characterized by recurrent episodes of partial or complete upper airway obstruction occurring during sleep, leading to chronic intermittent hypoxia (CIH). This hallmark is the main factor involved in cardiovascular remodelling in OSA 1 . In OSA patients, early signs of atherosclerosis correlated to hypoxia severity 2 , even after adjustment for confounding factors. OSA is associated with increased cardiovascular morbidity and mortality, and is identified as an independent cardiovascular risk factor (CVRF) 3 . Moreover, exposure of apolipoprotein E-deficient (ApoE -/-) mice 4, 5 and C57BL/6J mice 6 to CIH accelerated atherogenesis progression.
Atherosclerosis is a chronic inflammatory disease. Among the many inflammatory mediators involved in atherogenesis, we previously demonstrated the contribution of arachidonic acid (AA)-derived metabolites in OSA patients. Notably, OSA patients exhibited elevated levels of leukotriene B 4 7, 8 and cysteinyl-leukotrienes 9 , that were associated with vascular remodelling.
However, the cyclooxygenase (COX)-dependant pathway of AA metabolism was poorly studied in OSA patients, and its implication in CIH-induced atherogenesis is unknown.
Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two COX-derived metabolites of AA metabolism. TXA 2 is predominantly generated by platelets through COX type 1 isoform (COX-1) and thromboxane synthase (TXBS). TXA 2 is quickly metabolized on thromboxane B 2 (TXB 2 ) and 11-dehydrothromboxane B 2 (11-dTXB 2 ), two metabolites respectively quantifiable in plasma and urine. TXA 2 binding on its TP receptors (TPr) induces platelet activation, vasoconstriction, vascular smooth muscle cell proliferation and increases expression of adhesion molecules 10 . The production of PGI 2 mainly depends on endothelial COX-2 and prostacyclin synthase (PGIS). PGI 2 is rapidly metabolized on 6-ketoPGF1α in plasma and 2,3-dinor-6ketoPGF1α (PGI-M) excreted in urine. In contrast to TXA 2 , PGI 2 binding on its IP receptors (IPr) inhibits platelet aggregation and vasoconstriction, and reduces chemotaxis and expression of adhesion molecules 10 . Thus, TXA 2 and PGI 2 have antagonist properties.
A recent growing body of evidence suggests a major role of the COX pathway in the pathogenesis and progression of atherosclerosis. In fact, pharmacological inhibition of COX pathway 11, 12 or genetic deletion 13, 14 delayed atherosclerosis in different mouse models of atherosclerosis. Furthermore, the urinary 11-dTXB 2 /PGI 2 -M ratio is enhanced in elderly subjects with past history of serious cardiovascular event (stroke and myocardial infarction) 15 .
Since selective COX-2 inhibitors may have non-favourable effects on this ratio and increase cardiovascular risk 16 , the role of COX-1 inhibition has received less attention. In addition, data in OSA are very limited and conflicting showing either an increased 17 or a decreased 18 urinary ratio 11-dTXB 2 /PGI 2 -M. Thus, the aim of the present study was to characterize the COX pathway in ApoE -/-mice exposed to CIH and in OSA patients, and to investigate its link with CIH-induced atherogenesis and OSA-associated early vascular remodelling. M. Supernatants were immediately frozen at -80°C for prostanoid measurement, while aortas were dried for measurement of dry tissue weight.
Materiel and methods

Experimental
COX-pathway gene expression
Total mRNA was isolated from aorta using the RNeasy kit (Qiagen ® ) as previously 
Design
The specific contribution of CIH on 11-dTXB 2 urinary concentrations was assessed in 25 controls carefully matched for age and body mass index (BMI) with 50 non-obese OSA patients (1 healthy for 2 OSA). All subjects were free of any known CVRF. A sample size of 50 OSA patients and 25 controls was calculated as adequate to show an increase of 30% in urinary 11-dTXB 2 excretion with at least 90% power and at the 5% significance level. This sample size calculation was based on preliminary data obtained on healthy subjects showing a mean concentration of 11-dTXB 2 of 647 pg/ml with a standard deviation of 287 pg/ml. Since the dispersion of 11-dTXB 2 was higher in patients with cardiovascular disease than in controls, we chose a mixt model including 1 healthy for 2 OSA. All subjects underwent an overnight polysomnography as described 9 . Sleep apnea was defined as apnea-hypopnea index (AHI) ≥5 events per hour of sleep and symptoms or respiratory disturbance index (RDI), including flow limitation episodes >15 events per hour 21 .
Urine sample for 11-dTXB 2 quantification and venous blood for biochemical measurements were collected at 7 AM at the end of the nocturnal polysomnographic recordings and were stored at -80 °C until later analysis.
Carotid ultrasonography was performed in 97 OSA patients and 24 controls as previously 
Biological measurements
Plasma cholesterol, triglycerides, glucose and high sensitivity C reactive protein (hsCRP) concentrations were determined using enzymatic colorimetric methods on Dimension Vista ® analyser (Siemens ® ). LDL cholesterol was calculated using the Friedewald formula [total cholesterol-HDL cholesterol-(triglycerides/5)]. Urinary 11-dTXB 2 of patients, TXB 2 and 6-ketoPGF1α in supernatants of mice were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described 9, 22 . The limits of quantitation of TXB 2 and 6-ketoPGF1α were respectively 14 pg/ml and 7.25 pg/ml and their inter-and intra-assay coefficients of variation were < 12% for both analytes.
Statistical analysis
Statistical analyses were performed using NCSS97 (Kaysville, Utah) or SAS (SAS 9. 
Results
Experimental animal study
Weight, lipid levels and hematocrit
After 8 week-exposure, body weight and plasma cholesterol levels were similar in CIH and N mice (Table 1) . Hematocrit was significantly higher in CIH mice compared to N mice (Table   1) .
Atherosclerotic lesion sizes
Atherosclerotic lesions on aortic roots were higher (p=0.008) in CIH mice compared to N mice (CIH: 66532 (32741-163224) vs. N: 37675 (6798-75596) µm²; p=0.03). Lesion sizes correlated with plasma total cholesterol in N mice (r=0.501, p=0.04) but not in CIH mice.
COX-pathway gene expression
COX-1 and TXBS aortic mRNA levels were significantly increased in CIH group compared to N, whereas COX-2, PGIS, TP and IP receptors aortic mRNA levels were not significantly different between both groups (Figure 1a) . mRNA levels of COX-1 and TXBS significantly correlated with lesion sizes (Figure 1b) .
Aortic prostanoid secretion
A23187-stimulated 6-ketoPGF1 and TXB 2 secretions and 6-ketoPGF1/TXB 2 ratio were similar in aorta from CIH and N mice ( Table 2 ). 6-ketoPGF1 and TXB 2 concentrations were highly correlated (r=0.842, p<0.0001).
Effects of COX-1 inhibition
In both N and CIH groups, treatment with SC-560 significantly decreased TXB 2 and 6-ketoPGF1α aortic secretion vs. placebo (Table 2 ). There was no difference between groups for total cholesterol and body weight ( Table 2) . Treatment with SC-560 significantly reduced lesion size by 35% in CIH mice whereas it had no effect in N mice (Figure 2 ).
Clinical study
11-dTXB 2 and OSA
Baseline characteristics of the 25 controls and the 50 OSA patients matched for age and BMI are described in Table 3 . There was no significant difference for plasma insulin, hsCRP, HDL cholesterol, HOMA'R, BP, carotid intima-media thickness (IMT) and gender ratio. As expected, polysomnographic parameters were different between OSA and control groups.
Plasma glucose, total and LDL cholesterol levels were significantly increased in OSA patients versus controls. Urinary 11-dTXB 2 was not significantly different between OSA patients and controls (Table 3) .
11-dTXB 2 , OSA and cardiovascular risk factor
Clinical, biological and polysomnographic parameters of OSA patients with or without CVRF are shown in Table 4 . OSA group with CVRF had polysomnographic parameters, BP, BMI, plasma triglycerides, total and LDL cholesterol, glucose, insulin and HOMA'R higher than OSA group free of CVRF (Table 4) . Conversely, these 2 groups were similar regarding age, gender ratio, carotid IMT, HDL cholesterol and hsCRP (Table 4 ). Urinary 11-dTXB 2 was significantly increased in OSA patients with CVRF compared to OSA patients free of CVRF (Figure 3a) . In OSA patients with or without CVRF, 11-TXB 2 levels were similar in patients with mild to moderate (AHI <30events/h) and severe OSA (AHI ≥30events/h) (data not shown).
To determine the CVRF involved in the increase of urinary 11-dTXB 2 , simple regressions were performed. Hypertension (r=0.190, p=0.05) and obesity (r=0.242, p=0.01) were weakly associated with increased urinary excretion of 11-dTXB 2 . In multiple regression model, obesity remained the sole independent predictive factor of urinary 11-dTXB 2 (r=0.257, p=0.04).
Effect of CPAP treatment on urinary 11-dTXB 2 concentration
CPAP treatment for at least 8 weeks significantly decreased AHI, RDI and respiratory arousal index, increased minimal nocturnal SaO 2 and mean nocturnal SaO 2 , and decreased the percentage of time spent with a mean SaO 2 less than 90%. CPAP treatment induced no change on 11-dTXB 2 urinary concentration in OSA without or with CVRF (supplemental online Table 2 and Table 3 ).
11-dTXB 2 , OSA and vascular remodelling
In OSA patients free of CVRF, vascular hypertrophy (defined by carotid IMT>0.8mm) was associated with increased urinary 11-dTXB 2 concentrations compared to subjects without vascular hypertrophy (p=0.02) (Figure 3b ).
Discussion
Our study demonstrated for the first time an activation of the COX pathway in ApoE -/-mice exposed to CIH and in OSA patients with other CVRF; this activation being associated with higher atherosclerosis lesions in mice and with early markers of atherosclerosis in OSA patients.
We showed that CIH mice had higher atherosclerotic lesions than N mice, suggesting that, in our model, CIH might have accelerated atherosclerosis development. This result is in accordance with previous works in ApoE -/-mice exposed to CIH from 2 to 4 weeks 4, 5 or in C57BL/6J mice exposed to CIH for 12 weeks 6 .
In the present study, plasma cholesterol levels were not significantly different between N and CIH groups and atherosclerotic lesion sizes correlated with plasma cholesterol in N mice, but not in CIH mice. These data suggested that, in our model, CIH-induced atherosclerosis might be independent of lipid disorders and contrasted with previous works showing that concomitant exposure to high-fat high-cholesterol diet and CIH aggravated both atherosclerosis and dyslipidemia in ApoE -/-mice 4 and in C57BL/6J mice 6, 23 . However, we recently showed that CIH also exerts pro-atherogenic effect through other contributing factors, notably the inflammatory process 5 . In agreement with this later hypothesis, our data showed an activation of the thromboxane pathway in CIH mice since mRNA levels of COX-1 and TXBS were increased in aortic tissue of CIH mice. Furthermore, the correlation between these mRNA levels and atherosclerotic lesion size was consistent with direct effects of TXA 2 on macrophages 24 . Unexpectedly, the aortic secretion of TXB 2 and 6-ketoPGF1α, as well as, the TXB 2 /6-ketoPGF1α ratio were similar in CIH and N mice. These results could be explained by the fact that we measured prostanoid secretion after aorta stimulation with A23187, and not the basal aortic production. A previous study performed in LDL r-KO mice demonstrated that the acceleration of atherogenesis in response to high fat diet was associated to increased basal levels of TXB 2 and 6-ketoPGF1α in aortic arch 25 , but measurements of prostanoids were performed by ELISA, which is not a specific method.
We chose to measure TXB 2 and 6-ketoPGF1α upon aorta stimulation with A23187 to obtain detectable prostanoid levels by our analytical technique (liquid chromatography-tandem mass spectrometry) which is highly specific but probably less sensitive. However, in our model, A23187 appears to stimulate TXB 2 and 6-ketoPGF1α release to the same extend since both levels were highly correlated, which could explain the similar TXB 2 /6-ketoPGF1α ratio in aorta from CIH and N mice. We acknowledge that comparisons of basal TXB 2 and 6-ketoPGF1α production and western blot analysis of COX-1 and TXBS would have been of interest with regard to the increased mRNA levels of COX-1 and TXBS induced by CIH, and that their lack may represent limitations of our study. ; so, it was of interest to explore the effects of COX-1 inhibition on established atherosclerotic lesions.
As previously described 12 , treatment with SC-560 had no effect on established atherosclerotic lesions in N mice, although it was effective in inhibiting COX-1 pathway as assessed by the measurement of aortic TXB 2 and 6-ketoPGF1α secretion. Collectively, these data demonstrated that in ApoE -/-mice, the atherogenic process was accelerated by CIH exposure, at least in part through COX-1 pathway activation. CIH activates leukocytes 26 and OSA patients display leukocyte activation 7, 8, 27 . By regulating the interaction between leukocytes, smooth muscle cells and endothelial cells, TXA 2 promotes and PGI 2 prevents the initiation and progression of atherogenesis 14 .
To extend to OSA patients the thromboxane-pathway activation observed in CIH mice, we measured the urinary excretion of 11-dTXB 2 , a validated biomarker of systemic TXA 2 production 10 . Urinary 11-dTXB 2 concentrations of OSA patients free of CVRF were not different to those of controls carefully matched for age and BMI, two major confounding factors often present in studies focused on the underlying inflammation associated to OSA.
These data suggested that OSA itself was not associated to an increased urinary 11-dTXB 2 excretion, an hypothesis confirmed by the observation that CPAP treatment had no influence on urinary 11-dTXB 2 level. However, increased urinary 11-dTXB 2 concentrations have previously been described in patients with cardiovascular diseases including obesity 28 and hypertension 29 . Consistent with these data, we showed that OSA patients with associated CVRF had higher urinary concentrations of 11-dTXB 2 than OSA patients free of known CVRF. Furthermore, among the studied CVRF, obesity was the sole independent predictor of urinary 11-dTXB 2 excretion, which is in agreement with a previous study demonstrating an increased urinary 11-dTXB 2 excretion in obese women 28 . This result provided further evidence for the major role of obesity in AA metabolism activation in OSA patients, as we previously described for the 5-lipooxygenase pathway 9 . Finally, urinary 11-dTXB 2 excretion was associated with carotid wall hypertrophy in OSA patients. Again, these findings were consistent with the proliferative effects of TXA 2 on vascular smooth muscle cells 10 , although it must be kept in mind that vascular remodelling is a complex process implying many mediators and that COX pathway activation might not be the sole mechanism of vascular remodelling in OSA patients with CVRF.
In conclusion, our study showed an activation of COX-1 pathway in ApoE high-sensitivity C reactive protein; IMT, intima-media thickness; 11-dTXB 2 , 11-dehydrothromboxane.
